World's Best Scientists 2026 revealed!
Marcin Kowanetz

Marcin Kowanetz

D-Index & Metrics

Biology and Biochemistry

D-Index
57
Citations
33755
World Ranking
13503
National Ranking
5726

Marcin Kowanetz publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Marcin Kowanetz sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 176 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Marcin Kowanetz D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Marcin Kowanetz sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 57 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Marcin Kowanetz is affiliated with Genentech in the United States and has contributed extensively to the field of medicine, with a focus on oncology. Their research spans 65 publications in medicine, including 35 specifically dedicated to oncology and additional works in radiology, nuclear medicine, imaging, pulmonary and respiratory medicine, immunology, and molecular biology.

The scientist's main research topics include cancer immunotherapy and biomarkers, with 22 publications in this area; monoclonal and polyclonal antibodies research, with 18 publications; lung cancer treatments and mutations, with 16 publications; colorectal cancer treatments and studies, with 14 publications; radiopharmaceutical chemistry and applications, with 14 publications; immunotherapy and immune responses, with 10 publications; and CAR-T cell therapy research, with 8 publications.

Marcin Kowanetz has authored influential papers including:

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy, 2020, Science Translational Medicine
  • Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, 2020, Nature Cancer
  • Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade, 2021, Journal for ImmunoTherapy of Cancer
  • Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer, 2020, Clinical Lung Cancer
  • Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors, 2021, Cancer Research

Frequent coauthors collaborating with Marcin Kowanetz include:

  • David Dornan, 12 publications
  • Michael N. Alonso, 12 publications
  • Shelley E. Ackerman, 11 publications
  • Alexander I. Spira, 10 publications
  • Karla A. Henning, 7 publications

Common publication venues for Marcin Kowanetz's work are:

  • Cancer Research (8 publications)
  • Regular and Young Investigator Award Abstracts (5 publications)
  • Journal of Clinical Oncology (3 publications)
  • Journal of Thoracic Oncology (2 publications)
  • Science Translational Medicine (1 publication)

Best Publications

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Howard J West;Michael McCleod;Maen Hussein;Alessandro Morabito

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • TGF-β and the Smad Signaling Pathway Support Transcriptomic Reprogramming during Epithelial-Mesenchymal Cell Transition

    Ulrich Valcourt;Marcin Kowanetz;Hideki Niimi;Carl-Henrik Heldin

  • Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective

    M. Kowanetz;N. Ferrara

  • Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

    Marcin Kowanetz;Xiumin Wu;John Lee;Martha Tan

  • G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

    Farbod Shojaei;Xiumin Wu;Xueping Qu;Marcin Kowanetz

  • Id2 and Id3 Define the Potency of Cell Proliferation and Differentiation Responses to Transforming Growth Factor β and Bone Morphogenetic Protein

    Marcin Kowanetz;Ulrich Valcourt;Rosita Bergström;Carl-Henrik Heldin

  • Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

    Solange Peters;Scott Gettinger;Melissa L. Johnson;Pasi A. Jänne

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

    Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  • Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo.

    Christian Sundberg;Marcin Kowanetz;Lawrence F Brown;Michael Detmar

  • Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses

    Susumu Itoh;Midory Thorikay;Marcin Kowanetz;Aristidis Moustakas

  • Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

    Louis Fehrenbacher;Joachim von Pawel;Keunchil Park;Achim Rittmeyer

  • A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

    Roy S. Herbst;Michael S. Gordon;Gregg Daniel Fine;Jeffrey Alan Sosman

  • IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

    Robert M. Jotte;Federico Cappuzzo;Ihor Vynnychenko;Daniil Stroyakovskiy

  • Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

    Omid Hamid;Jeffrey Alan Sosman;Donald P. Lawrence;Ryan J. Sullivan

Frequent Co-Authors

Priti Hegde
Priti Hegde Genentech
Scott N. Gettinger
Scott N. Gettinger Yale University
Napoleone Ferrara
Napoleone Ferrara University of California, San Diego
David R. Gandara
David R. Gandara University of California, Davis
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David R. Spigel
David R. Spigel Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education can open the door to a variety of specialized careers connected to biology and biochemistry. For those interested in human health and diet, online nutrition degrees provide a flexible path to enter fields like dietetics, wellness coaching, or public health.

If your focus is healthcare leadership, pursuing top cahme-accredited mha programs gives you advanced skills to manage hospitals or health organizations. These programs are highly respected in the healthcare industry and can be completed online to fit your schedule.

For nursing professionals, a dnp program no clinical is an excellent option to advance your expertise without the need for on-site clinical work. This can help you transition to policy, education, or executive roles in healthcare.

Additionally, if you want to research and shape healthcare systems at the highest level, a phd in healthcare management prepares you for academic, consulting, or high-level administrative positions.

Best Scientists Citing Marcin Kowanetz

Trending Scientists

Recently Published Articles